We identified 16 CTAGs (27%) in our RFE set (S3) as being highly discriminatory for survivorship in this distinct cohort of NSCLC patients (SPATA19, SPACA3, TSGA10, TSPY3, LUZP4, TCEA2, CTNNA2, MAGEB2, SPO11, MAGEB4, MAEL, CSAG1, MAGEB5, COX6B2, GAGE2 and TSSK6). This evidence concerns the gene COX6B2 and non-small cell lung carcinoma.